Cargando…

Corrigendum: Safety of Semaglutide

Detalles Bibliográficos
Autores principales:	Smits, Mark M., Van Raalte, Daniël H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631750/ https://www.ncbi.nlm.nih.gov/pubmed/34858353 http://dx.doi.org/10.3389/fendo.2021.786732

Ejemplares similares

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
por: Nauck, Michael A., et al.
Publicado: (2021)

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
por: Meier, Juris J.
Publicado: (2021)

Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
por: Gallwitz, Baptist, et al.
Publicado: (2021)

Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials
por: Zhang, Rui, et al.
Publicado: (2023)

Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
por: Niu, Shu, et al.
Publicado: (2022)

Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
por: Pérez-Belmonte, Luis M., et al.
Publicado: (2022)

Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice
por: Yue, Lin, et al.
Publicado: (2022)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
por: Pratley, Richard E, et al.
Publicado: (2020)

Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
por: Garcia de Lucas, Maria Dolores, et al.
Publicado: (2022)

Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice
por: Zhu, Ruiyi, et al.
Publicado: (2023)

Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis
por: Patel, Tirath, et al.
Publicado: (2023)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
por: Meier, Juris J., et al.
Publicado: (2021)

Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report
por: Martínez-Montoro, José Ignacio, et al.
Publicado: (2022)

Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01)
por: Berra, Cesare C., et al.
Publicado: (2023)

Corrigendum: Update on genistein and thyroid: an overall message of safety
por: Marini, Herbert, et al.
Publicado: (2022)

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes
por: Smits, Mark M, et al.
Publicado: (2015)

Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study
por: García de Lucas, María Dolores, et al.
Publicado: (2023)

An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review
por: Dagli, Namrata, et al.
Publicado: (2023)

A Review on the Efficacy and Safety of Oral Semaglutide
por: Niman, Stephanie, et al.
Publicado: (2021)

Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study
por: Volpe, Sara, et al.
Publicado: (2023)

Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs)
por: Anam, Mahvish, et al.
Publicado: (2022)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

Efficacy and safety of semaglutide in non-alcoholic fatty liver disease
por: Zhu, Kai, et al.
Publicado: (2023)

Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
por: Bækdal, Tine A., et al.
Publicado: (2018)

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
por: Granhall, Charlotte, et al.
Publicado: (2018)

Glycemic Control and the Weight Benefit of a Daily 7 mg Dose of Oral Semaglutide Versus an Alternate-Day 14 mg Dose of Oral Semaglutide From an Ambulatory Glucose Monitoring Data: A Retrospective Cohort Study From Eastern India
por: RoyChaudhuri, Soumyabrata, et al.
Publicado: (2023)

Corrigendum: Low Testosterone in Adolescents & Young Adults
por: Cohen, Jordan, et al.
Publicado: (2020)

Semaglutide-associated bullous pemphigoid
por: Burruss, Clayton P., et al.
Publicado: (2021)

Corrigendum: Sparse system identification of leptin dynamics in women with obesity
por: Amin, Md. Rafiul, et al.
Publicado: (2022)

Corrigendum: Signaling Pathways Regulating Thermogenesis
por: Tabuchi, Chihiro, et al.
Publicado: (2021)

Semaglutide for type 2 diabetes
Publicado: (2020)

Semaglutide-eye-catching results
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2023)

Emerging Anesthesia Risks with Semaglutide
por: Fezza, Reed, et al.
Publicado: (2023)

Corrigendum: the FMRFamide-like peptide family in nematodes
por: Peymen, Katleen, et al.
Publicado: (2015)

Corrigendum: Biased Signaling of Protease-Activated Receptors
por: Zhao, Peishen, et al.
Publicado: (2015)

Corrigendum: Thyroid Hormone Action on Innate Immunity
por: Montesinos, María del Mar, et al.
Publicado: (2019)

Corrigendum: Common pitfalls in the interpretation of endocrine tests
por: Alvarez-Payares, Jose C., et al.
Publicado: (2022)

Corrigendum: Dose-Dependent and Lasting Influences of Intranasal Vasopressin on Face Processing in Men
por: Price, Daniel, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0vbbefkhm54odncppjcs2h0h6f